Joe represents clients in life sciences, advising them on various commercial and intellectual property transactions, including licensing and collaboration agreements, along with broader corporate transactions involving intellectual property.
SiteOne Therapeutics to Be Acquired by Eli Lilly for up to $1 Billion
May 28, 2025
Cooley advised SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, on its acquisition by Eli Lilly.
Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical
March 17, 2025
Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.
Chimerix Announces Acquisition by Jazz Pharmaceuticals for $935 Million
March 5, 2025
Cooley advised Chimerix (Nasdaq: CMRX), a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, on its definitive agreement to be acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) for $8.55 per share in cash – totaling approximately $935 million.
